Pacira BioSciences, Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
PCRX$36.49+0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
| Number of Shares Outstanding · AdditionalPaid-InCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome | ||||||||
|---|---|---|---|---|---|---|---|---|
| Common Shares · Treasury Shares · Common Stock · Treasury Stock · Total | ||||||||
| Balance at June 30, 2025 | 47,691 | (2,793) | $48 | $(75,515) | $1,035,563 | $(206,391) | $4,062 | $757,767 |
| Exercise of stock options | 1 | — | — | — | 12 | — | — | 12 |
| Vested restricted stock units | 43 | — | — | — | (1) | — | — | (1) |
| Common stock withheld for employee withholding tax liabilities on vested restricted stock units | — | — | — | — | (7) | — | — | (7) |
| Stock-based compensation | — | — | — | — | 13,978 | — | — | 13,978 |
| Purchase of treasury stock, inclusive of excise tax and broker fees | — | (1,976) | — | (50,028) | — | — | — | (50,028) |
| Other comprehensive income (Note 11) | — | — | — | — | — | — | 61 | 61 |
| Net income | — | — | — | — | — | 5,432 | — | 5,432 |
| Balance at September 30, 2025 | 47,735 | (4,769) | $48 | $(125,543) | $1,049,545 | $(200,959) | $4,123 | $727,214 |
| Number of Shares Outstanding · AdditionalPaid-InCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome | ||||||||
|---|---|---|---|---|---|---|---|---|
| Common Shares · Treasury Shares · Common Stock · Treasury Stock · Total | ||||||||
| Balance at June 30, 2024 | 46,954 | (837) | $47 | $(25,121) | $983,178 | $(78,931) | $105 | $879,278 |
| Vested restricted stock units | 31 | — | — | — | — | — | — | — |
| Common stock withheld for employee withholding tax liabilities on vested restricted stock units | — | — | — | — | (32) | — | — | (32) |
| Stock-based compensation | — | — | — | — | 13,230 | — | — | 13,230 |
| Other comprehensive income (Note 11) | — | — | — | — | — | — | 573 | 573 |
| Net loss | — | — | — | — | — | (143,466) | — | (143,466) |
| Balance at September 30, 2024 | 46,985 | (837) | $47 | $(25,121) | $996,376 | $(222,397) | $678 | $749,583 |
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
| Number of Shares Outstanding · AdditionalPaid-InCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome | ||||||||
|---|---|---|---|---|---|---|---|---|
| Common Shares · Treasury Shares · Common Stock · Treasury Stock · Total | ||||||||
| Balance at December 31, 2024 | 47,078 | (837) | $47 | $(25,121) | $1,009,435 | $(206,356) | $343 | $778,348 |
| Exercise of stock options | 1 | — | — | — | 12 | — | — | 12 |
| Vested restricted stock units | 765 | — | 1 | — | — | — | — | 1 |
| Common stock withheld for employee withholding tax liabilities on vested restricted stock units | (210) | — | — | — | (5,474) | — | — | (5,474) |
| Common stock issued under employee stockpurchase plan | 101 | — | — | — | 1,569 | — | — | 1,569 |
| Stock-based compensation | — | — | — | — | 44,003 | — | — | 44,003 |
| Purchase of treasury stock, inclusive of excise tax and broker fees | — | (3,932) | — | (100,422) | — | — | — | (100,422) |
| Other comprehensive income (Note 11) | — | — | — | — | — | — | 3,780 | 3,780 |
| Net income | — | — | — | — | — | 5,397 | — | 5,397 |
| Balance at September 30, 2025 | 47,735 | (4,769) | $48 | $(125,543) | $1,049,545 | $(200,959) | $4,123 | $727,214 |
| Number of Shares Outstanding · AdditionalPaid-InCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome | ||||||||
|---|---|---|---|---|---|---|---|---|
| Common Shares · Treasury Shares · Common Stock · Treasury Stock · Total | ||||||||
| Balance at December 31, 2023 | 46,481 | — | $46 | $— | $976,633 | $(106,796) | $247 | $870,130 |
| Vested restricted stock units | 448 | — | 1 | — | — | — | — | 1 |
| Common stock withheld for employee withholding tax liabilities on vested restricted stock units | — | — | — | — | (414) | — | — | (414) |
| Common stock issued under employee stockpurchase plan | 56 | — | — | — | 1,364 | — | — | 1,364 |
| Stock-based compensation | — | — | — | — | 38,905 | — | — | 38,905 |
| Purchase of treasury stock, inclusive of excise tax | — | (837) | — | (25,121) | — | — | — | (25,121) |
| Purchase of capped call transaction, net of tax | — | — | — | — | (20,112) | — | — | (20,112) |
| Other comprehensive income (Note 11) | — | — | — | — | — | — | 431 | 431 |
| Net loss | — | — | — | — | — | (115,601) | — | (115,601) |
| Balance at September 30, 2024 | 46,985 | (837) | $47 | $(25,121) | $996,376 | $(222,397) | $678 | $749,583 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.